News | July 21, 2021
EMA grants ODD to Saroglitazar Mg
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
